415 related articles for article (PubMed ID: 15031776)
1. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
Luboshitzky R; Herer P; Shen-Orr Z
Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
[TBL] [Abstract][Full Text] [Related]
2. Cyproterone acetate-ethinyl estradiol treatment alters urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women.
Luboshitzky R; Herer P; Shen-Orr Z
Neuro Endocrinol Lett; 2002 Aug; 23(4):309-13. PubMed ID: 12195232
[TBL] [Abstract][Full Text] [Related]
3. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment.
Luboshitzky R; Shen-Orr Z; Herer P; Nave R
Gynecol Endocrinol; 2003 Dec; 17(6):441-7. PubMed ID: 14992162
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Spona J; Huber J; Schmidt JB
Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
[TBL] [Abstract][Full Text] [Related]
6. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
Chung JP; Yiu AK; Chung TK; Chan SS
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
[TBL] [Abstract][Full Text] [Related]
7. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
[TBL] [Abstract][Full Text] [Related]
8. Increased urinary 6-sulfatoxymelatonin excretion in women with non-classical steroid 21-hydroxylase deficiency.
Luboshitzky R; Qupti G; Ishay A; Shen-Orr Z; Herer P
Neuro Endocrinol Lett; 2001 Oct; 22(5):332-6. PubMed ID: 11600882
[TBL] [Abstract][Full Text] [Related]
9. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study.
Naka KK; Kalantaridou SN; Bechlioulis A; Kravariti M; Kazakos N; Katsouras CS; Tsatsoulis A; Michalis LK
Gynecol Endocrinol; 2011 Sep; 27(9):615-21. PubMed ID: 21329419
[TBL] [Abstract][Full Text] [Related]
10. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
Franks S; Layton A; Glasier A
Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
[TBL] [Abstract][Full Text] [Related]
11. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
[TBL] [Abstract][Full Text] [Related]
13. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
[TBL] [Abstract][Full Text] [Related]
14. Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6months therapy: correlation with androgen levels.
Kos-Kudła B; Małecka-Mikosz O; Foltyn W; Ostrowska Z; Kudła M; Mazur B
Neuro Endocrinol Lett; 2006 Dec; 27(6):763-7. PubMed ID: 17187005
[TBL] [Abstract][Full Text] [Related]
15. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
16. Treatment of female hyperandrogenism: estroprogestinic therapy at low dose in an inversal sequential scheme.
Ragonesi FP; Lo Mastro F; Arena V; Ermini M
Acta Eur Fertil; 1995; 26(4):141-3. PubMed ID: 9098476
[TBL] [Abstract][Full Text] [Related]
17. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
Vrbikova J; Dvorakova K; Hill M; Starka L
Endocr Regul; 2006 Dec; 40(4):119-23. PubMed ID: 17201585
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
Inal MM; Yildirim Y; Taner CE
Fertil Steril; 2005 Dec; 84(6):1693-7. PubMed ID: 16359967
[TBL] [Abstract][Full Text] [Related]
19. Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome.
Luboshitzky R; Qupti G; Ishay A; Shen-Orr Z; Futerman B; Linn S
Fertil Steril; 2001 Sep; 76(3):506-10. PubMed ID: 11532473
[TBL] [Abstract][Full Text] [Related]
20. [Ovarian suppression with Diane 35/50].
Erdmann D; Schindler EM; Schindler AE
Geburtshilfe Frauenheilkd; 1994 Nov; 54(11):627-33. PubMed ID: 8719015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
